Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minnelide alone or with Paclitaxel in Advanced Gastric Cancer
NCT05566834Phase 1Recruiting
- Sponsor
- Minneamrita Therapeutics LLC
- Start
- Nov 2020
- Primary completion
- Jun 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of minnelide in gastric cancer (GC) (2 arms), sponsored by Minneamrita Therapeutics LLC. Primary endpoint: Treatment Emergent Adverse Events at 24 months. Started Nov 2020; status: recruiting.
02
Drugs
minnelide
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05566834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566834.